14. Prevalencia de gammapatías monoclonales en una población estadounidense de alto riesgo
Artículo
REVISTA ORIGINAL

Palabras clave

Gammapatía monoclonal
GMSI
Espectometría de masas

Abstract

Este estudio tiene como objetivo evaluar la prevalencia y las implicaciones clínicas de las gammapatías monoclonales en una población estadounidense de alto riesgo examinada mediante espectrometría de masas. Se sugiere la asociación de esta patología con diferentes fenotipos clínicos y con una disminución de la supervivencia global.

 

This study aims to assess the prevalence and clinical implications of monoclonal gammopathies in a high-risk US population examined by mass spectrometry. The study suggests the association of monoclonal gammopathies with a variety of clinical phenotypes and decreased overall survival.

 

 

 

  • Recibido: 06 Abril 2023
  • Revisión: 11 Abril 2023
  • Aceptado: 05 Mayo 2023
Artículo
REVISTA ORIGINAL

Citas

Vol 34 N12; págs. 3111-3125. 2020. Ho M, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G.

Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined

significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia.

Doi: https://doi.org/10.1038/s41375-020-01051-x

Vol 198 N4; págs. 641-653. 2022. Giles HV, Wechalekar A, Pratt G. The potential role of mass

spectrometry for the identification and monitoring of patients with plasma cell disorders: Where

are we now and which questions remain unanswered? . British Journal Haematology.

Doi: https://doi.org/10.1111/bjh.18226

Vol 18 N5; págs 391-396. 2018. Atkin C, Richter A, Sapey E. What is the significance of

monoclonal gammopathy of undetermined significance? . Clin Med (Lond).

Doi: https://doi.org/10.7861%2Fclinmedicine.18-5-391

Vol 116 N15; págs. 2651-2655. 2010. Kristinsson SY, Tang M, Pfeiffer RM et al. Monoclonal

gammopathy of undetermined significance and risk of skeletal fractures: a population-based

study. Blood.

Doi: https://doi.org/10.1182/blood-2010-04-282848

Vol 61 N2; págs. 140-144. 1998. Gregersen H, Madsen KM, Sørensen HT et al. The risk of

bacteremia in patients with monoclonal gammopathy of undetermined significance. European

Journal of Haematology.

Doi: https://doi.org/10.1111/j.1600-0609.1998.tb01075.x

Vol 115 N24; págs 4991-4998. 2010. Kristinsson SY, Pfeiffer RM, Björkholm M et al. Arterial

and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple

myeloma: a population-based study. Blood.

Doi: https://doi.org/10.1182/blood-2009-11-252072

Vol 15 N3; págs. 177-186. 2015. Go RS, Gundrum JD, Neuner JM. Determining the clinical

significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare

population analysis. Clinical Lymphoma Myeloma & Leukemia.

Doi: https://doi.org/10.1016%2Fj.clml.2014.09.004

Vol 378 N3; págs. 241-249.2018. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S,

Cerhan JR, Rajkumar SV. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined

Significance. The New England Journal of Medicine.

Doi: https://doi.org/10.1056/nejmoa1709974